Alfalfa infection model: Is it a potential alternative for mouse pneumonia model to study pathogenesis of Stenotrophomonas maltophilia?

World Journal of Microbiology and Biotechnology

Volumn 25, Issue 9, 2009, Pages 1609-1614

  Sharan, Riti ^a   Chhibber, Sanjay ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Alfalfa seedlings; Cystic fibrosis; Mouse pneumonia model; Stenotrophomonas maltophilia

Indexed keywords

ALFALFA SEEDLINGS; CYSTIC FIBROSIS; DISEASE SYMPTOMS; INFECTION MODELS; PLANT MODEL; STENOTROPHOMONAS MALTOPHILIA; VIRULENCE FACTORS; VIRULENCE POTENTIAL;

STRAIN;

BACTERIA (MICROORGANISMS); MEDICAGO SATIVA; STENOTROPHOMONAS MALTOPHILIA;

EID: 71349083685     PISSN: 09593993     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11274-009-0052-0     Document Type: Article

References (13)

1. Bernier SP, Silo-Suh L, Woods DE, Ohman DE, Sokol PA (2003) Comparative analysis of plant and animal models for characterization of Burkholderia cepacia virulence. Infect Immun 71: 5306-5313. doi: 10. 1128/IAI. 71. 9. 5306-5313. 2003.
2. Burns JL, Emerson J, Stapp JR, Darlene LY, Krzewinski J, Louden L, Ramsey BW, Clausen CR (1998) Microbiology of sputum from patients at cystic fibrosis centers in the US. Clin Infect Dis 27: 158-163. doi: 10. 1086/514631.
3. Chhibber S, Gupta A, Sharan R, Gautam V, Ray P (2008) Putative virulence characteristics of Stenotrophomonas maltophilia: a study on clinical isolates. World J Microbiol Biotechnol 24: 2819-2825. doi: 10. 1007/s11274-008-9812-5.
4. Chu KK, Davidson DJ, Halsey JW, Chung JW, Speert DP (2002) Differential persistence among genomovars of the Burkholderia cepacia complex in a murine model of pulmonary infection. Infect Immun 70: 2715-2720. doi: 10. 1128/IAI. 70. 5. 2715-2720. 2002.
5. Gabriel PS, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L (2004) Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 48: 168-171. doi: 10. 1128/AAC. 48. 1. 168-171. 2004.
6. Gilligan PH, Lum G, Vandamme PAR, Whitttier S (2003) Burkholderia, Stenotrophomonas, Ralstonia, Brevundimonas, Comamonas, Delftia, Pandoraea, and Acidovorax. In: Murray PR, Baron EJ, Pfaller MA, Jorgensen JH, Yolken RH (eds) Manual of clinical microbiology, 8th edn. ASM Press, Washington, pp 729-748.
7. Lasalsa PR, Segal J, Han FS, Tarrand JJ, Han XY (2007) First reported infections caused by three newly described genera in the family Xanthomonadaceae. J Clin Microbiol 45: 641-644. doi: 10. 1128/JCM. 01938-06.
8. Moss RB (2002) Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 121: 55-63. doi: 10. 1378/chest. 121. 1. 55.
9. Olivier KN, Weber DJ, Wallace RJ, Fiaz AR, Lee JH, Zhang Y, Elliot BAB, Handler A, Wilson RW, Schechter MS, Edwards LJ, Chakraborti S, Knowles MR (2003) Nontuberculous mycobacteria, I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 167: 828-834. doi: 10. 1164/rccm. 200207-678OC.
10. Silo-Suh L, Suh SJ, Sokol PA, Ohman DE (2002) A simple alfalfa seedling infection model for Pseudomonas aeruginosa strains associated with cystic fibrosis shows Alg T (Sigma 22) and RhlR contribute to pathogenesis. Proc Natl Acad Sci USA 99: 15699-15704. doi: 10. 1073/pnas. 242343999.
11. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 103: 8487-8492. doi: 10. 1073/pnas. 0602138103.
12. Traczewski MM, Brown SD (2004) In vitro activity of Doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother 50: 819-821. doi: 10. 1128/AAC. 50. 2. 819-821. 2006.
13. Waters VJ, Gomez MI, Soong G, Amin S, Ernst R, Prince A (2007) Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect Immun 75: 1698-1703. doi: 10. 1128/IAI. 01469-06.